Back to top
more

Mesoblast Limited (MESO)

(Delayed Data from NSDQ)

$17.00 USD

17.00
164,742

-0.43 (-2.47%)

Updated Aug 21, 2026 04:00 PM ET

After-Market: $17.02 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for Mesoblast (MESO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.

Zacks Equity Research

Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More

by Zacks Equity Research

The biotech sector remains in focus with regulatory and other pipeline updates.

Zacks Equity Research

Company News for Aug 17, 2020

by Zacks Equity Research

Companies in the news are: AMAT, MESO, NVAX, SKYS

Zacks Equity Research

Mesoblast Gets Favorable Votes From FDA Committee for Ryoncil

by Zacks Equity Research

Mesoblast (MESO) gets ODAC's vote in the ratio of 9:1 for GVHD drug.

Sweta Jaiswal, FRM headshot

Biotech ETFs Gaining on Progress in Coronavirus Treatment

by Sweta Jaiswal, FRM

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron

Zacks Equity Research

Pluristem Up on Cell Therapy Treatment of Coronavirus Patient

by Zacks Equity Research

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

Ekta Bagri headshot

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

by Ekta Bagri

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Zacks Equity Research

Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.

Zacks Equity Research

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.